Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. (ORKA): 7 pipeline candidates · 7 upcoming catalysts · ~48 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
47.6 months
D/E 0.04 · 0% dilution
Lead: Phase 2
7 candidates
7 upcoming, next in ~196d
0 buys · 36 sells (180d)
A transparent, data-derived signal for Oruka Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.3B
Cash
$49.5M
Quarterly Burn
$23.6M
Runway
47.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| gencaro | — |
| orka-001 | Phase 1 |
| orka-001 induction dose | Phase 2 |
| orka-001 maintenance dose | Phase 2 |
| orka-002 | Phase 1 |
| orka-003 | Phase 2 |
| orka-021 | Phase 2 |
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
182
Total value held
$2.36B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,431,403 | $364.5M |
| vanguard capital management llc | 3,719,262 | $182.4M |
| blackrock, inc. | 3,527,087 | $173.0M |
| remedium capital partners, llc | 3,454,776 | $169.5M |
| perceptive advisors llc | 2,791,002 | $136.9M |
| viking global investors lp | 2,666,690 | $130.8M |
| rtw investments, lp | 2,058,148 | $101.0M |
| deep track capital, lp | 2,034,203 | $99.8M |
| avidity partners management lp | 1,520,848 | $89.3M |
| state street corp | 1,613,461 | $79.1M |
Showing top 10 of 182 institutional holders of Oruka Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Oruka Therapeutics, Inc.'s pipeline?
Oruka Therapeutics, Inc. (ORKA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Oruka Therapeutics, Inc.'s next catalyst?
Oruka Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: orka-001" — expected December 31, 2026.
What is Oruka Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Oruka Therapeutics, Inc. has approximately 47.6 months of cash runway.
What is Oruka Therapeutics, Inc.'s market capitalization?
Oruka Therapeutics, Inc.'s market capitalization is approximately $4.3B.
Who is the CEO of Oruka Therapeutics, Inc.?
Dr. Lawrence Otto Klein Ph.D. is the chief executive officer of Oruka Therapeutics, Inc. (ORKA).
Get the full picture on Oruka Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.